| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 22/02/2024 | 22:15 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:IMGN | ImmunoGen Inc |
| 14/02/2024 | 23:01 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:IMGN | ImmunoGen Inc |
| 12/02/2024 | 22:48 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMGN | ImmunoGen Inc |
| 12/02/2024 | 22:33 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:IMGN | ImmunoGen Inc |
| 12/02/2024 | 15:32 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | NASDAQ:IMGN | ImmunoGen Inc |
| 12/02/2024 | 13:52 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IMGN | ImmunoGen Inc |
| 12/02/2024 | 13:37 | PR Newswire (US) | AbbVie Completes Acquisition of ImmunoGen | NASDAQ:IMGN | ImmunoGen Inc |
| 05/02/2024 | 22:10 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:IMGN | ImmunoGen Inc |
| 01/02/2024 | 22:30 | Business Wire | ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:IMGN | ImmunoGen Inc |
| 29/01/2024 | 23:01 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:IMGN | ImmunoGen Inc |
| 12/01/2024 | 17:10 | PR Newswire (US) | Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law Firm | NASDAQ:IMGN | ImmunoGen Inc |
| 03/01/2024 | 00:10 | PR Newswire (US) | Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law Firm | NASDAQ:IMGN | ImmunoGen Inc |
| 02/01/2024 | 22:26 | Edgar (US Regulatory) | Form DEFM14A - Definitive proxy statement relating to merger or acquisition | NASDAQ:IMGN | ImmunoGen Inc |
| 21/12/2023 | 22:52 | Edgar (US Regulatory) | Form PREM14A - Preliminary proxy statements relating to merger or acquisition | NASDAQ:IMGN | ImmunoGen Inc |
| 20/12/2023 | 01:00 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:IMGN | ImmunoGen Inc |
| 10/12/2023 | 18:00 | Business Wire | ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH | NASDAQ:IMGN | ImmunoGen Inc |
| 08/12/2023 | 12:23 | IH Market News | Apple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest Updates | NASDAQ:IMGN | ImmunoGen Inc |
| 05/12/2023 | 13:46 | Dow Jones News | Immunogen Gets FDA Priority Review of Elahere Full Approval | NASDAQ:IMGN | ImmunoGen Inc |
| 30/11/2023 | 14:42 | Dow Jones News | ImmunoGen Shares Soar Premarket on Takeover by AbbVie | NASDAQ:IMGN | ImmunoGen Inc |
| 30/11/2023 | 14:13 | Dow Jones News | AbbVie to Buy ImmunoGen for More Than $10 Billion | NASDAQ:IMGN | ImmunoGen Inc |
| 30/11/2023 | 13:30 | PR Newswire (US) | AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio | NASDAQ:IMGN | ImmunoGen Inc |
| 02/11/2023 | 21:30 | Business Wire | ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference | NASDAQ:IMGN | ImmunoGen Inc |
| 02/11/2023 | 21:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IMGN | ImmunoGen Inc |
| 02/11/2023 | 11:30 | Business Wire | ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results | NASDAQ:IMGN | ImmunoGen Inc |
| 27/10/2023 | 12:30 | Business Wire | ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer | NASDAQ:IMGN | ImmunoGen Inc |
| 23/10/2023 | 14:30 | PR Newswire (US) | Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board | NASDAQ:IMGN | ImmunoGen Inc |
| 19/10/2023 | 22:01 | Business Wire | ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results | NASDAQ:IMGN | ImmunoGen Inc |
| 28/09/2023 | 13:00 | Business Wire | ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer | NASDAQ:IMGN | ImmunoGen Inc |
| 19/09/2023 | 23:37 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:IMGN | ImmunoGen Inc |
| 18/09/2023 | 12:30 | Business Wire | ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer | NASDAQ:IMGN | ImmunoGen Inc |